Unilife (UNIFF) 10-Q 12 May 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Mar. 31, 2014	8-May-14
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'UNIS	'
Entity Registrant Name	'Unilife Corp	'
Entity Central Index Key	'0001476170	'
Current Fiscal Year End Date	'--06-30	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	102,798,512

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Mar. 31, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Current Assets:	'	'
Cash and cash equivalents	$37,719	$5,736
Restricted cash	2,008	2,400
Accounts receivable	1,550	654
Inventories	63	71
Prepaid expenses and other current assets	675	409
Total current assets	42,015	9,270
Property, plant and equipment, net	46,686	46,106
Goodwill	11,625	11,498
Intangible assets, net	20	23
Other assets	1,424	1,504
Total assets	101,770	68,401
Current Liabilities:	'	'
Accounts payable	3,299	3,428
Accrued expenses	4,597	2,444
Current portion of long-term debt	645	3,826
Deferred revenue	'	3,010
Total current liabilities	8,541	12,708
Long-term debt, less current portion	55,111	20,045
Deferred revenue	18,358	50
Total liabilities	82,010	32,803
Contingencies (Note 9)	'	'
Stockholders' Equity:	'	'
Preferred stock, $0.01 par value, 50,000,000 shares authorized as of March 31, 2014; none issued or outstanding as of March 31, 2014 and June 30, 2013	'	'
Common stock, $0.01 par value, 250,000,000 shares authorized as of March 31, 2014; 102,827,182 and 95,602,558 shares issued, and 102,798,512 and 95,573,888 shares outstanding as of March 31, 2014 and June 30, 2013, respectively	1,028	956
Additional paid-in-capital	294,736	268,157
Accumulated deficit	-278,468	-235,832
Accumulated other comprehensive income	2,604	2,457
Treasury stock, at cost, 28,670 shares as of March 31, 2014 and June 30, 2013, respectively	-140	-140
Total stockholders' equity	19,760	35,598
Total liabilities and stockholders' equity	$101,770	$68,401

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Jun. 30, 2013
Statement Of Financial Position [Abstract]	'	'
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	'	'
Preferred stock, shares outstanding	'	'
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	102,827,182	95,602,558
Common stock, shares outstanding	102,798,512	95,573,888
Treasury stock, shares	28,670	28,670

Consolidated_Statements_of_Ope

Consolidated Statements of Operations and Comprehensive Loss (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Statement Of Income And Comprehensive Income [Abstract]	'	'	'	'
Revenue	$1,383	$685	$8,143	$2,076
Cost of product sales	'	46	'	127
Research and development	8,018	5,472	22,224	15,204
Selling, general and administrative	6,649	7,255	19,872	22,159
Depreciation and amortization	1,026	1,415	3,068	4,003
Total operating expenses	15,693	14,188	45,164	41,493
Operating loss	-14,310	-13,503	-37,021	-39,417
Interest expense	809	591	5,640	1,852
Interest income	-6	-10	-17	-48
Other income	-4	'	-8	'
Net loss	-15,109	-14,084	-42,636	-41,221
Other comprehensive loss	'	'	'	'
Foreign currency translation	-429	-49	-147	-217
Comprehensive loss	($14,680)	($14,035)	($42,489)	($41,004)
Net loss per share:	'	'	'	'
Basic and diluted net loss per share	($0.15)	($0.17)	($0.44)	($0.52)

Consolidated_Statement_of_Stoc

Consolidated Statement of Stockholders' Equity (USD $)	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income [Member]	Treasury Stock [Member]
In Thousands, except Share data
Beginning balance at Jun. 30, 2013	$35,598	$956	$268,157	($235,832)	$2,457	($140)
Beginning balance, shares at Jun. 30, 2013	'	95,602,558	'	'	'	'
Net loss	-42,636	'	'	-42,636	'	'
Foreign currency translation	147	'	'	'	147	'
Share-based compensation expense	6,875	8	6,867	'	'	'
Share-based compensation expense, shares	'	803,000	'	'	'	'
Issuance of common stock from public offerings, net of issuance costs	16,856	50	16,806	'	'	'
Issuance of common stock from public offerings, net of issuance costs, shares	5,012,153	5,012,153	'	'	'	'
Issuance of common stock upon exercise of stock options	2,920	14	2,906	'	'	'
Issuance of common stock upon exercise of stock options, shares	'	1,409,471	'	'	'	'
Ending balance at Mar. 31, 2014	$19,760	$1,028	$294,736	($278,468)	$2,604	($140)
Ending balance, shares at Mar. 31, 2014	'	102,827,182	'	'	'	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Cash flows from operating activities:	'	'
Net loss	($42,636)	($41,221)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	3,068	4,003
Share-based compensation expense	6,875	7,198
Recognition of deferred revenue	-3,187	-1,939
Non-cash interest expense	3,610	'
Changes in assets and liabilities:	'	'
Accounts receivable	137	965
Inventories	8	137
Prepaid expenses and other current assets	-268	-44
Other assets	-355	7
Accounts payable	781	-213
Accrued expenses	1,485	200
Deferred revenue	17,500	'
Net cash used in operating activities	-12,982	-30,907
Cash flows from investing activities:	'	'
Purchases of property, plant and equipment	-3,377	-1,931
Net cash used in investing activities	-3,377	-1,931
Cash flows from financing activities:	'	'
Proceeds from issuance of long-term debt	40,000	'
Principal payments on long-term debt and capital lease obligations	-11,061	-3,686
Proceeds from the issuance of common stock and warrants, net of issuance costs	16,856	32,162
Proceeds from the exercise of options to purchase common stock	2,534	171
Decrease in restricted cash	392	434
Payments of financing costs	-487	'
Net cash provided by financing activities	48,234	29,081
Effect of exchange rate changes on cash	108	18
Net increase (decrease) in cash and cash equivalents	31,983	-3,739
Cash and cash equivalents at beginning of period	5,736	11,410
Cash and cash equivalents at end of period	37,719	7,671
Supplemental disclosure of non-cash activities	'	'
Purchases of property, plant and equipment in accounts payable and accrued expenses	893	203
Purchases of property, plant and equipment pursuant to capital lease agreements	'	$74

Description_of_Business_and_Un

Description of Business and Unaudited Financial Statements	9 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Description of Business and Unaudited Financial Statements	'
	1. Description of Business and Unaudited Financial Statements
	Unilife Corporation and subsidiaries (the “Company”) is a U.S. based manufacturer and supplier of injectable drug delivery systems. The Company’s customers are biotechnology companies who seek to leverage its innovative, differentiated and customizable devices to enable or enhance the clinical development, regulatory approval and commercial lifecycles of its injectable biologics, drugs and vaccines. The Company manufactures and supplies its proprietary devices to pharmaceutical companies in a format where they can be filled and packaged with an injectable therapy prior to its shipment to the end-user for safe, simple and convenient administration.
	The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying unaudited consolidated financial statements contain all normal and recurring adjustments that, in the opinion of management, are necessary for a fair presentation for the periods presented as required by Rule 10-01 of Regulation S-X. Interim results may not be indicative of results for a full year. The accompanying unaudited consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the fiscal year ended June 30, 2013 contained in its Annual Report on Form 10-K.
	References to A$ mean the lawful currency of the Commonwealth of Australia. References to € or euros are to the lawful currency of the European Union.

Liquidity

Liquidity	9 Months Ended
	Mar. 31, 2014
Text Block [Abstract]	'
Liquidity	'
	2. Liquidity
	The Company has incurred recurring losses from operations during the year ended June 30, 2013, and the nine months ended March 31, 2014, and anticipates incurring additional losses until such time that it can generate sufficient revenue from the sale, customization, or exclusive use and licensing of its proprietary range of injectable drug delivery systems to pharmaceutical and biotechnology customers. Management has taken such steps delineated below to address its cash requirements.
	On March 12, 2014 (the “Closing Date”), Unilife Medical Solutions, Inc. (the “Borrower”), a wholly owned subsidiary of the Company, entered into a credit agreement (the “Credit Agreement”) with ROS Acquisition Offshore LP (together with its affiliates, successors, transferees and assignees, the “Lender”), an affiliate of OrbiMed Advisors. Pursuant to and subject to the terms of the Credit Agreement, the Lender agreed to provide term loans to the Borrower in the aggregate principal amount of up to $60.0 million. A first tranche loan of $40.0 million was drawn on the Closing Date and a further two tranches each of $10.0 million (collectively, the “Loans”) have been committed by the Lender and will be funded on each of December 15, 2014 and June 15, 2015, subject to and in accordance with the terms of the Credit Agreement.
	In October 2012, the Company entered into a Controlled Equity Offering Sales Agreement, (the “Sales Agreement”) pursuant to which the Company may, from time to time, issue and sell shares of common stock having an aggregate offering price of up to $45.0 million. During the nine months ended March 31, 2014, the Company issued 5,012,153 shares of common stock and raised approximately $16.9 million under the Sales Agreement. The Company is not obligated to make any additional sales of shares under the Sales Agreement. As of March 31, 2014, there was approximately $13.0 million available under the Sales Agreement.
	The Company continues to have discussions with current and prospective customers for many active programs in its commercial pipeline and has executed several agreements featuring a combination of revenue streams including exclusivity fees, device customization programs and supply contracts that have begun to generate cash payments to the Company during fiscal year 2014. The Company expects to continue to execute agreements and generate additional cash payments during the remainder of calendar year 2014. Given the substantial size, complexity and long-term duration of many of these prospective agreements, some can take a significant time to negotiate and finalize.
	The proceeds from the term loans under the Credit Agreement combined with anticipated cash to be generated from new and existing customer agreements are expected to provide the Company with sufficient liquidity. However, there can be no assurance that such cash from customer agreements will be available when needed. These factors continue to raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	3. Summary of Significant Accounting Policies
	Principles of Consolidation
	The consolidated financial statements include the accounts of Unilife Corporation and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
	Use of Estimates
	The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The estimates are principally in the areas of revenue recognition, royalty liability valuation and share-based compensation expense. Management bases its estimates on historical experience and various assumptions that are believed to be reasonable under the circumstances. Actual results could differ from those estimates.
	Inventories
	Inventories consist primarily of syringe components and include direct materials, direct labor and manufacturing overhead. Inventories are stated at the lower of cost or market, with cost determined using the first in, first out method. The Company routinely reviews its inventory for obsolete, slow moving or otherwise impaired inventory and records estimated impairments in the periods in which they occur.
	Share-Based Compensation
	The Company grants equity awards to its employees, directors, consultants and service providers. Certain employee and director awards vest over stated vesting periods and others also require achievement of specific performance or market conditions. The Company expenses the grant-date fair value of awards to employees and directors over their respective vesting periods. To the extent that employee and director awards vest only upon the achievement of a specific performance condition, expense is recognized over the period from the date management determines that the performance condition is probable of achievement through the date they are expected to be met. Awards granted to consultants and service providers are sometimes granted for past services, in which case their fair value is expensed on their grant date, while other awards require future service, or the achievement of performance or market conditions. Timing of expense recognition for consultant awards is similar to that of employee and director awards; however, aggregate expense is re-measured each quarter-end based on the then fair value of the award through the vesting date of the award. The Company estimates the fair value of stock options using the Black-Scholes option-pricing model, with the exception of market-based grants, which are valued based on the Monte Carlo option pricing model. Option pricing methods require the input of highly subjective assumptions, including the expected stock price volatility.
	Revenue Recognition
	The Company recognizes revenue from industrialization and development fees, licensing fees and product sales.
	The Company recognizes revenue from sales of products at the time of shipment when title passes to the customer. The Company recognizes up front, non-refundable fees ratably over the expected life of the related agreement. Revenue from industrialization and development fees is recognized upon achievement of the “at risk” milestone events, which represent the culmination of the earnings process related to such events. Milestones can include specific phases of projects such as product design, prototype availability, user tests, manufacturing proof of principle and the various steps to complete the industrialization of the product. The terms of these contracts provide for customer payments to be made to the Company as services are rendered or milestones are achieved. Payment terms are considered to be standard commercial terms. Revenue is recognized when each substantive milestone has been achieved and the Company has no future performance obligations related to the milestone. Fees for completed milestones which are dependent upon customer acceptance for non-refundable payment or, if paid, are refundable pending customer acceptance are recognized upon customer acceptance and the termination of refund rights.
	The Company recognized $0.4 million and $2.9 million of revenue during the three and nine months ended March 31, 2014, respectively on the milestone basis as follows:
	The Company recognized $0.1 million and $1.3 million of revenue during the three and nine months ended March 31, 2014, respectively, pursuant to a clinical supply agreement with a customer related to milestones that were completed during the period. This agreement provides for the customization of a drug delivery system to be used in combination with the customer’s product candidate in a clinical trial. This agreement provides for payments to be made upon the completion of agreed-upon milestones.
	The Company recognized $0 and $0.8 million of revenue during the three and nine months ended March 31, 2014, respectively, pursuant to a customization and commercial supply agreement with a customer related to milestones that were completed during the period. This agreement provides for the development and future supply of customized component parts for the customer to use in a drug-device combination product. This agreement provides for payments to be made during the development period based on completion of agreed-upon milestones.
	The Company recognized $0.2 million and $0.7 million of revenue during the three and nine months ended March 31, 2014, respectively, pursuant to a materials transfer agreement with a customer related to milestones that were completed during the period. This agreement provides for certain materials and related services to the customer as determined under the agreement. This agreement expires upon completion of the services and provides for payments to be made upon completion of agreed-upon milestones.
	The Company recognized $0.1 million and $0.1 million of revenue during the three and nine months ended March 31, 2014, respectively, pursuant to a collaborative research agreement with a customer related to milestones that were completed during the period. This agreement provides for certain materials and related services to the customer as determined under the agreement. This agreement expires upon completion of the services and provides for payments to be made upon completion of agreed-upon milestones.
	Fair Value Measurements
	In accordance with ASC 820, Fair Value Measurements and Disclosures, the Company measures fair value based on a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unoberservable inputs by requiring that observable inputs be used when available. The fair value hierarchy is broken down into three levels based on the source of inputs.
	The Company has elected to measure its royalty liability at fair value in accordance with ASC 825, Financial Instruments. The fair value of the royalty liability is based on significant inputs not observable in the market, which require it to be reported as a Level 3 liability within the fair value hierarchy. The valuation uses a methodology and assumptions the Company believes would be made by a market participant. In particular, the valuation analysis used a discounted cash flow methodology under the income approach based on the present value sum of payments to be made in the future. The fair value of the royalty liability is estimated by applying a risk adjusted discount rate to the adjusted royalty revenue stream. These fair value estimates are most sensitive to changes in the payment stream.
	Reclassifications
	Certain prior year amounts in the consolidated financial statements have been reclassified to conform to the current year presentation.
	Recently Issued Accounting Pronouncements
	In February 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2013-02, “Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income” (“ASU 2013-02”). The new guidance requires an entity to disclose in a single location the effects of reclassifications out of accumulated other comprehensive income (“AOCI”). For items reclassified out of AOCI and into net income in their entirety, entities must disclose the effect of the reclassification on each affected net income item. For AOCI reclassification items that are not reclassified in their entirety into net income, entities must provide a cross reference to other required U.S. GAAP disclosures. The standard does not change the items which must be reported in other comprehensive income. ASU 2013-02 is effective for annual and interim periods for fiscal years beginning after December 15, 2012. Since this guidance impacts presentation only, it has had no effect on the Company’s financial condition.
	In July 2013, the FASB issued ASC 2013-11, “Income Taxes — Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists” (“ASU 2013-11”) which is part of Accounting Standards Codification (“ASC”) 740: Income Taxes. The new guidance requires an entity to present an unrecognized tax benefit and an NOL carryforward, a similar tax loss, or a tax credit carryforward on a net basis as part of a deferred tax asset, unless the unrecognized tax benefit is not available to reduce the deferred tax asset component or would not be utilized for that purpose, then a liability would be recognized. ASU 2013-11 is effective for annual and interim periods for fiscal years beginning after December 15, 2013. The Company is currently evaluating the impact of the July 1, 2014 adoption of this guidance on its financial statements.

Equity_Transactions_and_ShareB

Equity Transactions and Share-Based Compensation	9 Months Ended
	Mar. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Equity Transactions and Share-Based Compensation	'
	4. Equity Transactions and Share-Based Compensation
	The Company recognized share-based compensation expense related to equity awards to employees, directors, consultants and service providers of $1.6 million and $2.7 million during the three months ended March 31, 2014 and 2013, respectively and $6.9 million and $7.2 million during the nine months ended March 31, 2014 and 2013, respectively.
	During the nine months ended March 31, 2014 the Company granted certain directors 227,500 shares of common stock which may not be sold or transferred until such time as the director leaves the board for any reason, including a change in control, or other permitted circumstances. The weighted average grant date fair value of the shares was $3.95 per share.
	Stock Options and Warrants
	The Company has granted stock options to certain employees and directors under the Employee Share Option Plan (the “Plan”). The Plan is designed to assist in the motivation and retention of employees and to recognize the importance of employees to the long-term performance and success of the Company. The Company has also granted stock options to certain consultants and service providers outside of the Plan. The majority of the options to purchase common stock vest on the anniversary of the date of grant, which ranges from one to three years. Additionally, certain stock options vest upon the closing price of the Company’s common stock reaching certain minimum levels, as defined in the agreements. Share-based compensation expense related to options granted to employees is recognized on a straight-line basis over the related vesting term. Share-based compensation expense related to options granted to consultants and service providers is recognized ratably over each vesting tranche of the options.
	In November 2009, the Company adopted the 2009 Stock Incentive Plan (the “Stock Incentive Plan”). The Stock Incentive Plan initially provided for a maximum of 6,000,000 shares of common stock to be reserved for the issuance of stock options and other stock-based awards. Commencing on January 1, 2012, and on each January 1st thereafter, through January 1, 2019, the share reserve automatically adjusts so that it equals 17.5% of the weighted average number of shares of common stock outstanding reduced by the sum of any shares of common stock issued under the Stock Incentive Plan and any shares of common stock subject to outstanding awards under the Stock Incentive Plan.
	In January 2010, the Company issued 1,000,000 options to purchase common stock to a consultant under the Stock Incentive Plan in consideration for various services to be performed for the Company. The options to purchase common stock are exercisable at A$6.33 per share and vest upon the trading price of the Company’s CHESS Depositary Interests reaching certain minimum levels on the Australian Securities Exchange, which range from A$1.75 to A$3.22 per share. The options are re-measured each reporting date and as of March 31, 2014 were valued at $0.31 per option, which is being expensed ratably over the vesting period of each tranche, which ranges from 0.57 years to 0.69 years. The options will be re-valued on a quarterly basis and marked to market until exercised.
	The following is a summary of activity related to stock options held by employees and directors during the nine months ended March 31, 2014:
		Number of			Weighted			Weighted		Aggregate Intrinsic
		Options			Average			Average		Value
					Exercise Price			Remaining
								Contractual
								Life (in years)
										(in thousands)
	Outstanding as of July 1, 2013		5,121,807		$	4.09
	Cancelled		(74,396	)		5.55
	Exercised		(1,250,000	)		1.83
	Outstanding as of March 31, 2014		3,797,411		$	4.81			5.2	$	1,571
	Exercisable as of March 31, 2014		2,042,157		$	4.61			5.8	$	806
	The following is a summary of activity related to stock options and warrants held by persons other than employees and directors during the nine months ended March 31, 2014:
		Number of			Weighted			Weighted		Aggregate Intrinsic
		Options			Average			Average		Value
					Exercise Price			Remaining
								Contractual
								Life (in years)
										(in thousands)
	Outstanding as of July 1, 2013		4,258,937		$	7.15
	Granted		300,000			3.11
	Exercised		(240,000	)		2.65
	Expired		(2,268,934	)		9.02
	Outstanding as of March 31, 2014		2,050,003		$	5.02			1.7	$	600
	Exercisable as of March 31, 2014		1,050,003		$	4.2			2.5	$	600
	The aggregate intrinsic value is defined as the difference between the market value of the Company’s common stock as of the end of the period and the exercise price of the in-the-money stock options. The total intrinsic value of stock options exercised during the three months ended March 31, 2014 and 2013 was $0.1 million and $0 respectively. The total intrinsic value of stock options exercised during the nine months ended March 31, 2014 and 2013 was $1.9 million and $0.1 million, respectively.
	The Company used the following weighted average assumptions in calculating the fair value of options granted during the nine months ended March 31, 2014 and 2013:
		Nine Months Ended
		March 31,
		2014			2013
	Number of stock options granted		300,000			660,000
	Expected dividend yield		0	%		0	%
	Risk-free interest rate		1.54	%		0.94	%
	Expected volatility		55	%		55	%
	Expected life (in years)		5			6
	The fair value of each stock option was estimated at the grant date using the Black-Scholes option pricing model, with the exception of grants subject to market conditions, which were valued using a Monte Carlo option pricing model. The Company has not historically paid dividends to its stockholders and, as a result, assumed a dividend yield of 0%. The risk free interest rate is based upon the rates of U.S. Treasury bonds with a term equal to the expected term of the option. Due to the Company’s limited Nasdaq trading history, the expected volatility used to value options granted after January 27, 2010 is based upon a blended rate of the historical share price of the Company’s stock on the Australian Securities Exchange and the volatility of peer companies traded on U.S. exchanges operating in the same industry as the Company. The expected term of the options to purchase common stock issued to employees and directors is based upon the simplified method, which is the mid-point between the vesting date of the option and its contractual term unless a reasonable alternate term is estimated by management. The expected term of the options to purchase common stock issued to consultants and service providers is based on the contractual term of the awards.
	Restricted Stock
	The Company has granted shares of restricted stock to certain employees’ consultants and service providers under the Stock Incentive Plan. During the period prior to vesting, the holder of the non-vested restricted stock will have the right to vote and the right to receive all dividends and other distributions declared. All non-vested shares of restricted stock are reflected as outstanding; however, they have been excluded from the calculation of basic earnings per share.
	For employees, the fair value of restricted stock is measured on the date of grant using the price of the Company’s common stock on that date. Share-based compensation expense for restricted stock issued to employees is recognized on a straight-line basis over the requisite service period, which is generally the longest vesting period. For restricted stock granted to consultants and service providers, the fair value of the awards is re-valued on a quarterly basis and marked to market until vested. Share-based compensation expense for restricted stock issued to consultants and service providers is recognized ratably over each vesting tranche.
	The following is a summary of activity related to restricted stock awards during the nine months ended March 31, 2014:
		Number of Restricted			Weighted Average
		Stock Awards			Grant Date Fair Value
	Unvested as of July 1, 2013		3,254,403		$	3.31
	Granted		530,000			4.41
	Vested		(1,400,892	)		3.18
	Cancelled		(4,500	)		3.46
	Unvested as of March 31, 2014		2,379,011		$	3.63

Property_Plant_and_Equipment_a

Property, Plant and Equipment and Construction-in-Progress	9 Months Ended
	Mar. 31, 2014
Property Plant And Equipment [Abstract]	'
Property, Plant and Equipment and Construction-in-Progress	'
	5. Property, Plant and Equipment and Construction-in-Progress
	Property, plant and equipment consist of the following:
		March 31,			June 30,
		2014			2013
		(in thousands)
	Building	$	32,188		$	32,188
	Machinery and equipment		19,338			21,682
	Computer software		2,661			2,653
	Furniture and fixtures		598			374
	Construction in progress		2,135			91
	Land		2,036			2,036
	Leasehold improvements		166			88
			59,122			59,112
	Less: accumulated depreciation and amortization		(12,436	)		(13,006	)
	Property, plant and equipment, net	$	46,686		$	46,106
	The Company has purchase commitments totaling $2.9 million related to expansion of its manufacturing space.

Goodwill

Goodwill	9 Months Ended
	Mar. 31, 2014
Goodwill And Intangible Assets Disclosure [Abstract]	'
Goodwill	'
	6. Goodwill
	The changes in the carrying amount of goodwill during the nine months ended March 31, 2014 are as follows:
		(in thousands)
	Balance as of July 1, 2013	$	11,498
	Foreign currency translation		127
	Balance as of March 31, 2014	$	11,625

LongTerm_Debt

Long-Term Debt	9 Months Ended
	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Long-Term Debt	'
	7. Long-Term Debt
	Long-term debt consists of the following:
		March 31, 2014		June 30, 2013
		(In thousands)
	10.25% Term loan, due March 2020	$	33,000	$	—
	Royalty agreement liability		7,000		—
	6.00% Mortgage loan, due December 2031		13,347		13,677
	6.00% Mortgage loan, due October 2020		—		3,322
	14.00% Secured lending facility, due December 2014		—		2,586
	4.75% Bank term loans, due January 2021 through August 2021		—		1,701
	5.00% Commonwealth of Pennsylvania financing authority loan, due January 2021		2,096		2,133
	Other		313		452
			55,756		23,871
	Less: current portion of long-term debt		645		3,826
	Total long-term debt	$	55,111	$	20,045
	Term Loan
	On March 12, 2014 the Borrower entered into the Credit Agreement with the Lender. Pursuant to and subject to the terms of the Credit Agreement, the Lender agreed to provide term loans to the Borrower in the aggregate principal amount of up to $60.0 million. A first tranche loan of $40.0 million was drawn on the Closing Date and a further two tranches each of $10.0 million have been committed by the Lender and will be funded on each of December 15, 2014 and June 15, 2015, subject to and in accordance with the terms of the Credit Agreement.
	The Loans bear interest at 9.25% per annum plus the greater of three-month LIBOR or 1.0%, payable in cash quarterly in arrears, and as otherwise described in the Credit Agreement. A default interest rate of 14.25% per annum plus the greater of three-month LIBOR or 1.0% shall apply during the existence of a default under the Credit Agreement. The Loans will be interest-only until March 12, 2020 (“the Maturity Date”).
	Unless the loan facility is otherwise terminated earlier pursuant to the terms of the Credit Agreement, the Borrower is required to repay in full the unpaid principal amount of the Loans drawn down, together with all accrued and unpaid interest thereon plus a 6.0% repayment premium on Maturity Date. The Borrower can make voluntary repayments at any time of any unpaid principal amount of the Loans, plus a 6.0% repayment premium. The Borrower must make mandatory prepayments in certain prescribed circumstances, including, without limitation, certain dispositions of assets and certain casualty events. In such events, the Borrower must prepay to Lender 100% of the net cash proceeds received.
	The obligations of the Borrower under the Credit Agreement are guaranteed by the Company and each of its subsidiaries and the Credit Agreement is secured by the assets of the Company and its subsidiaries. The security interests granted by Borrower, the Company, Unilife Cross Farm LLC (“Cross Farm”), Unilife Medical Solutions Limited (“USML”) and Unitract Syringe Pty Limited (“Unitract Syringe”) are evidenced by, among other things, the Pledge and Security Agreement, dated as of March 14, 2014, by the Borrower, the Company, Cross Farm, USML, and Unitract Syringe in favor of Lender, for itself and as agent for Royalty Opportunities S.A.R.L. (“ROS”), the Mortgage and Security Agreement, dated March 12, 2014, by and between Cross Farm and Lender, for itself and as agent of ROS, and the General Security Deed, dated as of March 12, 2014, by Unitract Syringe, USML, and the Company in favor of the Lender, for itself and as agent of ROS. The Credit Agreement also contains certain customary covenants, as well as, covenants relating to achieving minimum cash revenue targets at the end of each calendar year, maintaining minimum liquidity targets, the execution of certain customer agreements in form and substance satisfactory to lender within 90 days of closing and the retention of certain members of management.
	The Borrower received net proceeds of approximately $31.4 million following repayment of certain of our existing debt and certain fees and expenses of the Lender in connection with the Loans. In addition, the Borrower incurred approximately $0.4 million in other expenses in connection with the Loans.
	In connection with the Credit Agreement, the Borrower entered into a royalty agreement (the “Royalty Agreement”) with ROS which will entitle ROS to receive royalty payments. Pursuant to and subject to the terms of the Royalty Agreement, the borrower has agreed to pay 2.75% on the first $50.0 million of net sales (on a cash receipts basis as defined in the Credit Agreement) in each fiscal year, plus 1.0% of net sales in excess of $50.0 million and up to and including $100.0 million in each fiscal year, plus 0.25% of net sales in excess of $100.0 million in each fiscal year. Borrower has the right to buyout the Royalty Agreement at any time on or before the fourth anniversary of the agreement at a reduced amount. The buy-out amount ranges from $6.5 million, on or prior to the first anniversary of the agreement and up to $21.0 million, after the fourth anniversary of the agreement (such amount depending on when the buy-out option is exercised), less amounts previously paid by the Borrower to lender pursuant to the Royalty Agreement.
	The Company determined that the Credit Agreement and the Royalty Agreement should be accounted for as two separate units. Accordingly, the Company allocated the proceeds from the Loans on a prorated basis between the two units based on their relative fair values. As a result, on the Closing Date, the Loan was determined to have a fair value of $33.0 million and the Royalty Agreement was determined to have a fair value of $7.0 million. The Loan will be accreted to the face value over the loan term based on an effective interest rate of 17.5%. The Royalty Agreement will be adjusted to fair value on a quarterly basis.
	On the Closing Date, Cross Farm, the Borrower and the Company also entered into an Omnibus Waiver and Amendment (the “Metro Bank Amendment”), to that certain Loan Agreement dated as of October 20, 2010 by, among others, Cross Farm and Metro Bank and the other loan documents relating thereto (collectively, the “Original Metro Bank Loan Documents”) whereby Metro Bank was paid the amount of $40 thousand, in order to permit Unilife’s execution of the Credit Agreement and related documents and to extend its obligations to Lender thereunder, while remaining in compliance with the Original Metro Bank Loan Documents.
	Mortgage Loans
	In October 2010, Cross Farm entered into a loan agreement with Metro Bank, pursuant to which Metro Bank provided Cross Farm with two mortgage loans in the amounts of $14.25 million and $3.75 million. The proceeds received were used to finance the purchase of land and construction of the Company’s corporate headquarters and manufacturing facility in York, Pennsylvania.
	During construction, Cross Farm paid only interest on both mortgage loans at the Prime Rate plus 1.50% per annum, with a floor of 4.50% per annum. Subsequent to construction, Cross Farm is paying principal and interest on both mortgage loans, with interest at a fixed rate of 6.00%. The weighted average interest rate on both mortgage loans was 6.00% during the nine months ended March 31, 2014 and the year ended June 30, 2013. In connection with the two mortgage loans and other bank term loans, the Company has given Metro Bank a lien on substantially all of the Company’s assets except for the Company’s intellectual property and certain other assets that are subject to other third party liens.
	The Original Metro Loan Document contains certain customary covenants, including the maintenance of a Debt Service Reserve Account in the amount of $2.4 million, classified as restricted cash on the consolidated balance sheet, which will remain in place until Cross Farm and Metro agree on the financial covenants. The terms of the Original Metro Loan Documents allow the Company to use the Debt Service Reserve Account to pay monthly debt service on the mortgage loans, so long as the balance in the account is at least $1.6 million and is replenished to $2.4 million every six months. The Company was in compliance with its debt covenants as of March 31, 2014. However, there can be no assurance that the Company will be able to maintain the Debt Service Reserve Account balance for a period of 12 months from March 31, 2014. Cross Farm may prepay the loan without penalty. The U.S. Department of Agriculture has guaranteed $8.0 million of the mortgage loan due December 2031.
	In connection with the Credit Agreement, the Company entered into the Metro Bank Amendment pursuant to which the 6.0% Mortgage due October 2020 and the 4.75% term loans due January through August 2021 were repaid. The Company used proceeds from the March 12, 2014 Credit Agreement of $4.9 million to repay the mortgage and the term loans which included $0.1 million in fees and expenses paid to Metro bank. In addition the Company wrote-off approximately $0.1 million in unamortized deferred financing costs related to the mortgage. The total amount recognized during the three months ended March 31, 2014 as loss on early extinguishment of debt was $0.2 million. In exchange for the repayment of the mortgage and loans, Metro Bank agreed to release, effective March 12, 2014, the liens on substantially all of the Company’s assets except for the lien on the building and real estate in connection with the remaining mortgage and the debt service reserve account.
	Secured Lending Facility
	In August 2011, the Company entered into a Master Lease Agreement (the “Lease Agreement”) with Varilease Finance, Inc. (“Varilease”) for up to $10.0 million of secured financing for production equipment for its Unifill syringe. Based on the Company’s continuing involvement throughout the term of the agreement and the integral nature of the production equipment, the transaction is being accounted for as a financing. Over the term of the Lease Agreement, the Company made 27 monthly installments based upon the amount drawn. This facility had an effective interest rate of 14.00%. The secured lending facility contained covenants and provisions for events of default customarily found in lease agreements.
	As previously disclosed on September 30, 2013, Varilease and CCA Financial LLC (collectively, the “Lessors”) filed an action in the State of Michigan in the Circuit Court for the County of Oakland, Case No. 2013-136458-CK seeking a judgment confirming the terms of the lease. The Company removed the action to the U.S. District Court for the Eastern District of Michigan, Case No. 2:13-CV-14238-SFC-LJM, on October 4, 2013. Under the Lease Agreement, Lessors and the Company were to negotiate a buyout rate at the end of the two-year lease term, which Lessors represented to the Company during the lease negotiations would be 15% of the amount financed. When the Company notified Lessors that it wanted to exercise the buyout of the equipment, Lessors claimed a buyout rate significantly higher than 15%. Under the terms of the lease, if the parties are unable to agree on a buyout rate by the end of the lease term, the lease will automatically renew for an additional 12-month period and the Company would be responsible for another year of lease payments. Lessor’s action in Michigan state court asked the court to confirm that the parties have been unable to agree on a buyout rate and therefore under the terms of the lease the lease is automatically extended for one year.
	As previously disclosed, the Company also filed suit on September 30, 2013 against Lessors in the U.S. District Court for the Eastern District of Michigan, Case No. 2:13-cv-14174-SFC-LJM alleging, among other things, that Lessors fraudulently induced the Company into entering the lease by making misrepresentations about the buyout rate. The Company sought, among other things, to have the federal court enforce a 15% buyout rate and to enjoin Lessors from declaring a default under the lease and taking possession of the equipment for which the Company would have to impair the carrying value of assets. On October 17, 2013, in a stipulated order, the U.S. District Court ordered that the Company continue to make the same monthly payments under the lease, that as long as the Company makes timely payments, Lessors shall not declare a default, and that Lessors is required to provide advance notice of a default.
	As previously disclosed, the Company entered into a Confidential Mutual Release and Settlement Agreement (the “Definitive Settlement Agreement”), effective December 30, 2013, with the Lessors. The Definitive Settlement Agreement provides that it will obtain title to all equipment under the equipment lease upon the payment to the Lessors of approximately $4.8 million over the next twelve months. In addition, under the Definitive Settlement Agreement the Company and the Lessors released each other from any and all claims related to the companion lawsuits, as well as dismissed such lawsuits. In connection with the Definitive Settlement Agreement, during the nine months ended March 31, 2014, the Company recognized $3.6 million of interest expense representing the difference between the carrying value of the debt and the present value of the settlement amount.
	During the three months ended March 31, 2014, the Company paid $4.7 million (including $3.5 million with proceeds from the March 12, 2014 Credit Agreement) to the Lessors in satisfaction of the remaining obligation under the Definitive Settlement Agreement. Effective March 12, 2014 the Lessors released all liens and security interest in all of the Company’s assets subject to the Lease Agreement.
	Commonwealth of Pennsylvania Financing Authority Loan
	In December 2010, Cross Farm received a $2.25 million loan from the Commonwealth of Pennsylvania for land and the construction of its current manufacturing facility. The loan bears interest at a rate of 5.00% per annum, matures in January 2021 and is secured by a third mortgage on the facility. In connection with the loan agreement, Cross Farm entered into an intercreditor agreement by which the Commonwealth of Pennsylvania agreed that it would not exercise its rights in the event of a default by Cross Farm without the consent of Metro Bank, which holds the mortgage on the facility.

Net_Loss_Per_Share

Net Loss Per Share	9 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Net Loss Per Share	'
	8. Net Loss Per Share
	The Company’s net loss per share is as follows:
		Three Months Ended						Nine Months Ended
		March 31,						March 31,
		2014			2013			2014			2013
		(In thousands, except share and per share data)
	Numerator
	Net loss	$	(15,109	)	$	(14,084	)	$	(42,636	)	$	(41,221	)
	Denominator
	Weighted average number of shares used to compute basic net loss per share		100,007,135			81,595,444			97,135,688			78,830,613
	Effect of dilutive options to purchase common stock		—			—			—			—
	Weighted average number of shares used to compute diluted net loss per share		100,007,135			81,595,444			97,135,688			78,830,613
	Basic and diluted net loss per share	$	(0.15	)	$	(0.17	)	$	(0.44	)	$	(0.52	)
	Due to the Company’s net losses, unvested shares of restricted stock (participating securities) totaling 2,564,631 and 5,666,495 were excluded from the calculation of basic and diluted net loss per share during the three months ended March 31, 2014 and 2013, respectively and unvested shares of restricted stock (participating securities) totaling 2,774,977 and 5,200,496 were excluded from the calculation of basic and diluted net loss per share during the nine months ended March 31, 2014 and 2013, respectively.
	In addition, stock options (non-participating securities) totaling 3,429,685 and 7,032,057 during the three months ended March 31, 2014 and 2013, respectively, were excluded from the calculation of diluted net loss per share and stock options (non-participating securities) totaling 4,985,648 and 8,504,634 during the nine months ended March 31, 2014 and 2013, respectively, were excluded from the calculation of diluted net loss per share, as their effect would have been anti-dilutive. Certain of these stock options were excluded solely due to the Company’s net loss position. Had the Company reported net income during the three months ended March 31, 2014 and 2013, these shares would have had an effect of 493,490 and 914,744 diluted shares, respectively, for purposes of calculating diluted net loss per share. Had the Company reported net income during the nine months ended March 31, 2014 and 2013, these shares would have had an effect of 398,727 and 592,309 diluted shares, respectively, for purposes of calculating diluted net loss per share.

Contingencies

Contingencies	9 Months Ended
	Mar. 31, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Contingencies	'
	9. Contingencies
	From time to time, the Company is involved in various legal proceedings, claims, suits and complaints arising out of the normal course of business. Based on the facts currently available to the Company, management believes that these claims, suits and complaints are adequately provided for, covered by insurance, without merit or not probable that an unfavorable outcome will result.
	As previously disclosed, on September 7, 2012, the Company received a letter from counsel for Talbot (Todd) Smith, a former employee, alleging that Mr. Smith was wrongly terminated. Mr. Smith, who was terminated “for cause” by the Company, filed a complaint with the Occupational Safety & Health Administration (“OSHA”) in November 2012. The Company and various third parties have investigated the allegations made by Mr. Smith and have determined that the allegations are without merit. The Company believes the allegations made by Mr. Smith against the Company are in retaliation for his “for cause” termination and has been defending itself vigorously in the OSHA matter. Because OSHA did not make a final determination on Mr. Smith’s complaint within 180 days, Mr. Smith filed a complaint with the U.S. District Court for the Eastern District of Pennsylvania (the “USDC”) on August 30, 2013 and an amended complaint on March 5, 2014. The USDC amended complaint makes the same allegations made by Mr. Smith in the OSHA complaint and also includes a defamation claim, To the extent that the allegations made by Mr. Smith in the USDC complaint are nearly identical to those made in his OSHA complaint, the Company and various third parties have investigated the allegations previously and have determined that the allegations are without merit, and the Company will defend itself vigorously in court. The case is currently in discovery. Given that Mr. Smith filed the complaint with the USDC, OSHA dismissed the OSHA matter without a final determination.
	As previously disclosed, subsequent to the filing of the OSHA complaint by Mr. Smith on February 12, 2013, the Company received a subpoena from the staff of the U.S. Securities and Exchange Commission (the “Staff”) requesting the Company to provide certain information to the Staff, which is generally consistent with the meritless allegations made by Mr. Smith in his OSHA complaint. In the USDC complaint, Mr. Smith states that he provided the Staff with information about his allegations in July and August 2012. The Company responded to that subpoena and received additional subpoenas from the Staff, requesting additional information consistent with the first subpoena. The Company is cooperating fully with the Staff and is providing the requested information.
	On January 8, 2014, the Company was served with a derivative complaint filed in the Delaware Chancery Court by Cambridge Retirement System, a purported shareholder of the Company, against the Company’s Board of Directors to recover allegedly “excessive and wasteful” compensation paid to the non-executive directors since 2010. The Company believes that these allegations are baseless and without merit given that the Company has received favorable say-on-pay votes at the last three annual shareholders meetings and the shareholders previously have voted in favor of the equity grants to the directors, which is required under ASX listing rules, as recently as November 2013. The Company and the directors are defending themselves vigorously in this matter. The Company filed a motion to dismiss in lieu of an answer in February 2014 and expects that the court will hear oral arguments on the Company’s motion in June 2014.
	The Company does not believe there will be any material impact to the Company or its business as a result of these matters.

Sanofi_Agreements

Sanofi Agreements	9 Months Ended
	Mar. 31, 2014
Text Block [Abstract]	'
Sanofi Agreements	'
	10. Sanofi Agreements
	The Company signed an exclusivity agreement and an industrialization agreement with Sanofi, a multinational pharmaceutical company, between June 2008 and July 2009. Under the terms of these agreements, Sanofi had agreed to pay the Company an aggregate of approximately $36.4 million in exclusivity fees and industrialization milestone payments for the exclusive right to negotiate the purchase of the Unifill ready-to-fill (prefilled) syringe (Unifill syringe or product) which was developed pursuant to the agreements. Sanofi had paid the Company a €10.0 million ($13.0 million) up front non-refundable one-time fee which the Company was recognizing as revenue over the expected term of the agreement.
	On September 3, 2013, the Company and Sanofi entered into a supply agreement and terminated both the exclusivity agreement and the industrialization agreement. As a result, the Company has recognized the remaining unamortized revenue of $2.3 million during the nine months ended March 31, 2014. Under the terms of the supply agreement, the Company has granted Sanofi the exclusive use of the Unifill Finesse with anti-thrombotic drugs during the contract period. Following a four year ramp-up period after market entry, exclusivity will be maintained, subject to Sanofi purchasing a minimum of 150 million units of the Unifill Finesse or other Unifill syringes per year. The Company can supply its Unifill syringes, including the Unifill Finesse, to additional customers in all other therapeutic classes outside of anti-thrombotics. In addition to future revenue from the sale of Unifill Finesse syringes, the Company may receive up to $15 million from Sanofi in milestone-based payments with $5.0 million of these payments received in October 2013. This supply contract replaces and supersedes all other agreements previously signed between both parties regarding the Unifill syringe platform.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Principles of Consolidation	'
	Principles of Consolidation
	The consolidated financial statements include the accounts of Unilife Corporation and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	'
	Use of Estimates
	The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The estimates are principally in the areas of revenue recognition, royalty liability valuation and share-based compensation expense. Management bases its estimates on historical experience and various assumptions that are believed to be reasonable under the circumstances. Actual results could differ from those estimates.
Inventories	'
	Inventories
	Inventories consist primarily of syringe components and include direct materials, direct labor and manufacturing overhead. Inventories are stated at the lower of cost or market, with cost determined using the first in, first out method. The Company routinely reviews its inventory for obsolete, slow moving or otherwise impaired inventory and records estimated impairments in the periods in which they occur.
Share-Based Compensation	'
	Share-Based Compensation
	The Company grants equity awards to its employees, directors, consultants and service providers. Certain employee and director awards vest over stated vesting periods and others also require achievement of specific performance or market conditions. The Company expenses the grant-date fair value of awards to employees and directors over their respective vesting periods. To the extent that employee and director awards vest only upon the achievement of a specific performance condition, expense is recognized over the period from the date management determines that the performance condition is probable of achievement through the date they are expected to be met. Awards granted to consultants and service providers are sometimes granted for past services, in which case their fair value is expensed on their grant date, while other awards require future service, or the achievement of performance or market conditions. Timing of expense recognition for consultant awards is similar to that of employee and director awards; however, aggregate expense is re-measured each quarter-end based on the then fair value of the award through the vesting date of the award. The Company estimates the fair value of stock options using the Black-Scholes option-pricing model, with the exception of market-based grants, which are valued based on the Monte Carlo option pricing model. Option pricing methods require the input of highly subjective assumptions, including the expected stock price volatility.
Revenue Recognition	'
	Revenue Recognition
	The Company recognizes revenue from industrialization and development fees, licensing fees and product sales.
	The Company recognizes revenue from sales of products at the time of shipment when title passes to the customer. The Company recognizes up front, non-refundable fees ratably over the expected life of the related agreement. Revenue from industrialization and development fees is recognized upon achievement of the “at risk” milestone events, which represent the culmination of the earnings process related to such events. Milestones can include specific phases of projects such as product design, prototype availability, user tests, manufacturing proof of principle and the various steps to complete the industrialization of the product. The terms of these contracts provide for customer payments to be made to the Company as services are rendered or milestones are achieved. Payment terms are considered to be standard commercial terms. Revenue is recognized when each substantive milestone has been achieved and the Company has no future performance obligations related to the milestone. Fees for completed milestones which are dependent upon customer acceptance for non-refundable payment or, if paid, are refundable pending customer acceptance are recognized upon customer acceptance and the termination of refund rights.
	The Company recognized $0.4 million and $2.9 million of revenue during the three and nine months ended March 31, 2014, respectively on the milestone basis as follows:
	The Company recognized $0.1 million and $1.3 million of revenue during the three and nine months ended March 31, 2014, respectively, pursuant to a clinical supply agreement with a customer related to milestones that were completed during the period. This agreement provides for the customization of a drug delivery system to be used in combination with the customer’s product candidate in a clinical trial. This agreement provides for payments to be made upon the completion of agreed-upon milestones.
	The Company recognized $0 and $0.8 million of revenue during the three and nine months ended March 31, 2014, respectively, pursuant to a customization and commercial supply agreement with a customer related to milestones that were completed during the period. This agreement provides for the development and future supply of customized component parts for the customer to use in a drug-device combination product. This agreement provides for payments to be made during the development period based on completion of agreed-upon milestones.
	The Company recognized $0.2 million and $0.7 million of revenue during the three and nine months ended March 31, 2014, respectively, pursuant to a materials transfer agreement with a customer related to milestones that were completed during the period. This agreement provides for certain materials and related services to the customer as determined under the agreement. This agreement expires upon completion of the services and provides for payments to be made upon completion of agreed-upon milestones.
	The Company recognized $0.1 million and $0.1 million of revenue during the three and nine months ended March 31, 2014, respectively, pursuant to a collaborative research agreement with a customer related to milestones that were completed during the period. This agreement provides for certain materials and related services to the customer as determined under the agreement. This agreement expires upon completion of the services and provides for payments to be made upon completion of agreed-upon milestones.
Fair Value Measurements	'
	Fair Value Measurements
	In accordance with ASC 820, Fair Value Measurements and Disclosures, the Company measures fair value based on a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unoberservable inputs by requiring that observable inputs be used when available. The fair value hierarchy is broken down into three levels based on the source of inputs.
	The Company has elected to measure its royalty liability at fair value in accordance with ASC 825, Financial Instruments. The fair value of the royalty liability is based on significant inputs not observable in the market, which require it to be reported as a Level 3 liability within the fair value hierarchy. The valuation uses a methodology and assumptions the Company believes would be made by a market participant. In particular, the valuation analysis used a discounted cash flow methodology under the income approach based on the present value sum of payments to be made in the future. The fair value of the royalty liability is estimated by applying a risk adjusted discount rate to the adjusted royalty revenue stream. These fair value estimates are most sensitive to changes in the payment stream.
Reclassifications	'
	Reclassifications
	Certain prior year amounts in the consolidated financial statements have been reclassified to conform to the current year presentation.
Recently Issued Accounting Pronouncements	'
	Recently Issued Accounting Pronouncements
	In February 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2013-02, “Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income” (“ASU 2013-02”). The new guidance requires an entity to disclose in a single location the effects of reclassifications out of accumulated other comprehensive income (“AOCI”). For items reclassified out of AOCI and into net income in their entirety, entities must disclose the effect of the reclassification on each affected net income item. For AOCI reclassification items that are not reclassified in their entirety into net income, entities must provide a cross reference to other required U.S. GAAP disclosures. The standard does not change the items which must be reported in other comprehensive income. ASU 2013-02 is effective for annual and interim periods for fiscal years beginning after December 15, 2012. Since this guidance impacts presentation only, it has had no effect on the Company’s financial condition.
	In July 2013, the FASB issued ASC 2013-11, “Income Taxes — Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists” (“ASU 2013-11”) which is part of Accounting Standards Codification (“ASC”) 740: Income Taxes. The new guidance requires an entity to present an unrecognized tax benefit and an NOL carryforward, a similar tax loss, or a tax credit carryforward on a net basis as part of a deferred tax asset, unless the unrecognized tax benefit is not available to reduce the deferred tax asset component or would not be utilized for that purpose, then a liability would be recognized. ASU 2013-11 is effective for annual and interim periods for fiscal years beginning after December 15, 2013. The Company is currently evaluating the impact of the July 1, 2014 adoption of this guidance on its financial statements.

Equity_Transactions_and_ShareB1

Equity Transactions and Share-Based Compensation (Tables)	9 Months Ended
	Mar. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Schedule of Stock Options Activity by Employees and Directors	'
	The following is a summary of activity related to stock options held by employees and directors during the nine months ended March 31, 2014:
		Number of			Weighted			Weighted		Aggregate Intrinsic
		Options			Average			Average		Value
					Exercise Price			Remaining
								Contractual
								Life (in years)
										(in thousands)
	Outstanding as of July 1, 2013		5,121,807		$	4.09
	Cancelled		(74,396	)		5.55
	Exercised		(1,250,000	)		1.83
	Outstanding as of March 31, 2014		3,797,411		$	4.81			5.2	$	1,571
	Exercisable as of March 31, 2014		2,042,157		$	4.61			5.8	$	806
Schedule of Stock Options Activity by Other than Employees and Directors	'
	The following is a summary of activity related to stock options and warrants held by persons other than employees and directors during the nine months ended March 31, 2014:
		Number of			Weighted			Weighted		Aggregate Intrinsic
		Options			Average			Average		Value
					Exercise Price			Remaining
								Contractual
								Life (in years)
										(in thousands)
	Outstanding as of July 1, 2013		4,258,937		$	7.15
	Granted		300,000			3.11
	Exercised		(240,000	)		2.65
	Expired		(2,268,934	)		9.02
	Outstanding as of March 31, 2014		2,050,003		$	5.02			1.7	$	600
	Exercisable as of March 31, 2014		1,050,003		$	4.2			2.5	$	600
Fair Value of Options Granted	'
	The Company used the following weighted average assumptions in calculating the fair value of options granted during the nine months ended March 31, 2014 and 2013:
		Nine Months Ended
		March 31,
		2014			2013
	Number of stock options granted		300,000			660,000
	Expected dividend yield		0	%		0	%
	Risk-free interest rate		1.54	%		0.94	%
	Expected volatility		55	%		55	%
	Expected life (in years)		5			6
Summary of Activity Related to Restricted Stock Awards	'
	The following is a summary of activity related to restricted stock awards during the nine months ended March 31, 2014:
		Number of Restricted			Weighted Average
		Stock Awards			Grant Date Fair Value
	Unvested as of July 1, 2013		3,254,403		$	3.31
	Granted		530,000			4.41
	Vested		(1,400,892	)		3.18
	Cancelled		(4,500	)		3.46
	Unvested as of March 31, 2014		2,379,011		$	3.63

Property_Plant_and_Equipment_a1

Property, Plant and Equipment and Construction-in-Progress (Tables)	9 Months Ended
	Mar. 31, 2014
Property Plant And Equipment [Abstract]	'
Components of Property, Plant and Equipment and Construction-in-Progress	'
	Property, plant and equipment consist of the following:
		March 31,			June 30,
		2014			2013
		(in thousands)
	Building	$	32,188		$	32,188
	Machinery and equipment		19,338			21,682
	Computer software		2,661			2,653
	Furniture and fixtures		598			374
	Construction in progress		2,135			91
	Land		2,036			2,036
	Leasehold improvements		166			88
			59,122			59,112
	Less: accumulated depreciation and amortization		(12,436	)		(13,006	)
	Property, plant and equipment, net	$	46,686		$	46,106

Goodwill_Tables

Goodwill (Tables)	9 Months Ended
	Mar. 31, 2014
Goodwill And Intangible Assets Disclosure [Abstract]	'
Changes in Carrying Amount of Goodwill	'
	The changes in the carrying amount of goodwill during the nine months ended March 31, 2014 are as follows:
		(in thousands)
	Balance as of July 1, 2013	$	11,498
	Foreign currency translation		127
	Balance as of March 31, 2014	$	11,625

LongTerm_Debt_Tables

Long-Term Debt (Tables)	9 Months Ended
	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Components of Long-Term Debt	'
	Long-term debt consists of the following:
		March 31, 2014		June 30, 2013
		(In thousands)
	10.25% Term loan, due March 2020	$	33,000	$	—
	Royalty agreement liability		7,000		—
	6.00% Mortgage loan, due December 2031		13,347		13,677
	6.00% Mortgage loan, due October 2020		—		3,322
	14.00% Secured lending facility, due December 2014		—		2,586
	4.75% Bank term loans, due January 2021 through August 2021		—		1,701
	5.00% Commonwealth of Pennsylvania financing authority loan, due January 2021		2,096		2,133
	Other		313		452
			55,756		23,871
	Less: current portion of long-term debt		645		3,826
	Total long-term debt	$	55,111	$	20,045

Net_Loss_Per_Share_Tables

Net Loss Per Share (Tables)	9 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Net Loss Per Share	'
	The Company’s net loss per share is as follows:
		Three Months Ended						Nine Months Ended
		March 31,						March 31,
		2014			2013			2014			2013
		(In thousands, except share and per share data)
	Numerator
	Net loss	$	(15,109	)	$	(14,084	)	$	(42,636	)	$	(41,221	)
	Denominator
	Weighted average number of shares used to compute basic net loss per share		100,007,135			81,595,444			97,135,688			78,830,613
	Effect of dilutive options to purchase common stock		—			—			—			—
	Weighted average number of shares used to compute diluted net loss per share		100,007,135			81,595,444			97,135,688			78,830,613
	Basic and diluted net loss per share	$	(0.15	)	$	(0.17	)	$	(0.44	)	$	(0.52	)

Liquidity_Additional_Informati

Liquidity - Additional Information (Detail) (USD $)	0 Months Ended	9 Months Ended
	Mar. 12, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Oct. 31, 2012
			December 15, 2014 [Member]	June 15, 2015 [Member]	Maximum [Member]
Liquidity And Capital Resources [Line Items]	'	'	'	'	'
Committed principal amount of term loan	$60,000,000	'	'	'	'
Proceeds from tranche loan	40,000,000	40,000,000	10,000,000	10,000,000	'
Aggregate offering price	'	'	'	'	45,000,000
Number of shares of common stock issued	'	5,012,153	'	'	'
Remaining amount available under the Sales Agreement	'	13,000,000	'	'	'
Value of new stock issued	'	$16,856,000	'	'	'

Summary_of_Significant_Account2

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	3 Months Ended	9 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2014
Summary Of Significant Accounting Policies [Line Items]	'	'
Recognized revenue	$0.40	$2.90
Clinical Supply Agreement [Member]	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'
Recognized revenue	0.1	1.3
Customization and Commercial Supply Agreement [Member]	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'
Recognized revenue	0	0.8
Collaborative Research Agreement [Member]	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'
Recognized revenue	0.1	0.1
Materials Transfer Agreement [Member]	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'
Recognized revenue	$0.20	$0.70

Equity_Transactions_and_ShareB2

Equity Transactions and Share-Based Compensation - Additional Information (Detail)	0 Months Ended	3 Months Ended		9 Months Ended				0 Months Ended	9 Months Ended
In Millions, except Share data, unless otherwise specified	Nov. 30, 2009	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2014	Jan. 31, 2010	Mar. 31, 2014	Mar. 31, 2014
		USD ($)	USD ($)	USD ($)	USD ($)	Minimum [Member]	Maximum [Member]	Stock Incentive Plan [Member]	Employee Stock Option [Member]	Employee Stock Option [Member]
						AUD	AUD	AUD	Minimum [Member]	Maximum [Member]
Equity Transactions And Share Based Compensation [Line Items]	'	'	'	'	'	'	'	'	'	'
Share-based compensation expense	'	$1.60	$2.70	$6.90	$7.20	'	'	'	'	'
Issuance of common stock to directors	'	'	'	227,500	'	'	'	'	'	'
Grant date fair value	'	$0.31	'	$3.95	'	'	'	'	'	'
Fair value of the options being expensed, service period	'	'	'	'	'	'6 months 26 days	'8 months 9 days	'	'1 year	'3 years
Maximum shares not considered for sale and transfer	6,000,000	'	'	'	'	'	'	'	'	'
Share reserve adjustment percentage	17.50%	'	'	'	'	'	'	'	'	'
Granted options to purchase common stock	'	'	'	'	'	'	'	1,000,000	'	'
Price of exercisable options per share	'	'	'	'	'	'	'	6.33	'	'
Stock price requirement for vesting of options	'	'	'	'	'	1.75	3.22	'	'	'
Total intrinsic value	'	$0.10	$0	$1.90	$0.10	'	'	'	'	'
Expected dividend yield	'	'	'	0.00%	'	'	'	'	'	'

Equity_Transactions_and_ShareB3

Equity Transactions and Share-Based Compensation - Schedule of Stock Options Activity by Employees and Directors (Detail) (Employees and Directors [Member], USD $)	9 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014
Employees and Directors [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Number of Options, Beginning	5,121,807
Number of Options, Cancelled	-74,396
Number of Options, Exercised	-1,250,000
Number of Options, Ending	3,797,411
Number of Options, Exercisable	2,042,157
Weighted Average Exercise Price, Beginning	$4.09
Weighted Average Exercise Price, Cancelled	$5.55
Weighted Average Exercise Price, Exercised	$1.83
Weighted Average Exercise Price, Ending	$4.81
Weighted Average Exercise Price, Exercisable	$4.61
Weighted Average Remaining Contractual Life (in years), Outstanding	'5 years 2 months 12 days
Weighted Average Remaining Contractual Life (in years), Exercisable	'5 years 9 months 18 days
Aggregate Intrinsic Value, Outstanding	$1,571
Aggregate Intrinsic Value, Exercisable	$806

Equity_Transactions_and_ShareB4

Equity Transactions and Share-Based Compensation - Schedule of Stock Options Activity by Other than Employees and Directors (Detail) (Other Than Employees and Directors Warrants [Member], USD $)	9 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014
Other Than Employees and Directors Warrants [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Number of Options, Beginning	4,258,937
Number of Options, Granted	300,000
Number of Options, Exercised	-240,000
Number of Options, Expired	-2,268,934
Number of Options, Ending	2,050,003
Number of Options, Exercisable	1,050,003
Weighted Average Exercise Price, Beginning	$7.15
Weighted Average Exercise Price, Granted	$3.11
Weighted Average Exercise Price, Exercised	$2.65
Weighted Average Exercise Price, Expired	$9.02
Weighted Average Exercise Price, Ending	$5.02
Weighted Average Exercise Price, Exercisable	$4.20
Weighted Average Remaining Contractual Life (in years), Outstanding	'1 year 8 months 12 days
Weighted Average Remaining Contractual Life (in years), Exercisable	'2 years 6 months
Aggregate Intrinsic Value, Outstanding	$600
Aggregate Intrinsic Value, Exercisable	$600

Equity_Transactions_and_ShareB5

Equity Transactions and Share-Based Compensation - Fair Value of Options Granted (Detail)	9 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Expected dividend yield	0.00%	'
Stock Options [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Number of stock options granted	300,000	660,000
Expected dividend yield	0.00%	0.00%
Risk-free interest rate	1.54%	0.94%
Expected volatility	55.00%	55.00%
Expected life (in years)	'5 years	'6 years

Equity_Transactions_and_ShareB6

Equity Transactions and Share-Based Compensation - Summary of Activity Related to Restricted Stock Awards (Detail) (Restricted Stock [Member], USD $)	9 Months Ended
	Mar. 31, 2014
Restricted Stock [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Number of Restricted Stock Awards, Unvested, Beginning balance	3,254,403
Number of Restricted Stock Awards, Granted	530,000
Number of Restricted Stock Awards, Vested	-1,400,892
Number of Restricted Stock Awards, Cancelled	-4,500
Number of Restricted Stock Awards, Unvested, Ending balance	2,379,011
Weighted Average Grant Date Fair Value, Unvested, Beginning Balance	$3.31
Weighted Average Grant Date Fair Value, Granted	$4.41
Weighted Average Grant Date Fair Value, Vested	$3.18
Weighted Average Grant Date Fair Value, Cancelled	$3.46
Weighted Average Grant Date Fair Value, Unvested, Ending Balance	$3.63

Property_Plant_and_Equipment_a2

Property, Plant and Equipment and Construction-in-Progress - Components of Property, Plant and Equipment and Construction-in-Progress (Detail) (USD $)	Mar. 31, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Property Plant And Equipment [Abstract]	'	'
Building	$32,188	$32,188
Machinery and equipment	19,338	21,682
Computer software	2,661	2,653
Furniture and fixtures	598	374
Construction in progress	2,135	91
Land	2,036	2,036
Leasehold improvements	166	88
Property, plant and equipment, gross	59,122	59,112
Less: accumulated depreciation and amortization	-12,436	-13,006
Property, plant and equipment, net	$46,686	$46,106

Property_Plant_and_Equipment_a3

Property, Plant and Equipment and Construction-in-Progress - Additional Information (Detail) (Capital Addition Purchase Commitments [Member], USD $)	9 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014
Capital Addition Purchase Commitments [Member]	'
Property, Plant and Equipment [Line Items]	'
Purchase commitments related to expansion of manufacturing space	$2.90

Goodwill_Changes_in_Carrying_A

Goodwill - Changes in Carrying Amount of Goodwill (Detail) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014
Goodwill And Intangible Assets Disclosure [Abstract]	'
Beginning Balance	$11,498
Foreign currency translation	127
Ending Balance	$11,625

LongTerm_Debt_Components_of_Lo

Long-Term Debt - Components of Long-Term Debt (Detail) (USD $)	Mar. 31, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Debt Instrument [Line Items]	'	'
Long-term debt	$55,756	$23,871
Less: current portion of long-term debt	645	3,826
Total long-term debt	55,111	20,045
5.00% Commonwealth of Pennsylvania Financing Authority Loan, Due January 2021 [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	2,096	2,133
Other [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	313	452
10.25% Term Loan, Due March 2020 [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	33,000	'
Royalty Agreement Liability [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	7,000	'
6.00% Mortgage Loan, Due December 2031 [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	13,347	13,677
6.00% Mortgage Loan, Due October 2020 [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	'	3,322
14.00% Secured Lending Facility, Due December 2014 [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	'	2,586
4.75% Bank Term Loans, Due January 2021 Through August 2021 [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	'	$1,701

LongTerm_Debt_Components_of_Lo1

Long-Term Debt - Components of Long-Term Debt (Parenthetical) (Detail)	9 Months Ended
	Mar. 31, 2014
10.25% Term Loan, Due March 2020 [Member]	'
Debt Instrument [Line Items]	'
Long-term debt, percentage	10.25%
Long-term debt, due date	12-Mar-20
6.00% Mortgage Loan, Due December 2031 [Member]	'
Debt Instrument [Line Items]	'
Long-term debt, percentage	6.00%
Long-term debt, due date	31-Dec-31
6.00% Mortgage Loan, Due October 2020 [Member]	'
Debt Instrument [Line Items]	'
Long-term debt, percentage	6.00%
Long-term debt, due date	31-Oct-20
14.00% Secured Lending Facility, Due December 2014 [Member]	'
Debt Instrument [Line Items]	'
Long-term debt, percentage	14.00%
Long-term debt, due date	31-Dec-14
4.75% Bank Term Loans, Due January 2021 Through August 2021 [Member]	'
Debt Instrument [Line Items]	'
Long-term debt, percentage	4.75%
Long-term debt, due date	'January 2021 through August 2021
5.00% Commonwealth of Pennsylvania Financing Authority Loan, Due January 2021 [Member]	'
Debt Instrument [Line Items]	'
Long-term debt, percentage	5.00%
Long-term debt, due date	31-Jan-21

LongTerm_Debt_Additional_Infor

Long-Term Debt - Additional Information (Detail) (USD $)

0 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

9 Months Ended

9 Months Ended

9 Months Ended

9 Months Ended

3 Months Ended

Mar. 12, 2014

Sep. 30, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Jun. 30, 2013

Aug. 31, 2011

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2010

Mar. 31, 2014

Mar. 31, 2014

Jun. 30, 2013

Oct. 31, 2010

Oct. 31, 2010

Oct. 31, 2010

Mar. 31, 2014

Jun. 30, 2013

Mar. 31, 2014

Jun. 30, 2013

Mar. 31, 2014

Jun. 30, 2013

Mar. 31, 2014

Jun. 30, 2013

Mar. 31, 2014

Mar. 31, 2014

Tranches

Unit

Secured Lending Facility [Member]

Secured Lending Facility [Member]

Definitive Settlement Agreement [Member]

Definitive Settlement Agreement [Member]

Loan [Member]

Metro Bank [Member]

Royalty Agreements [Member]

December 15, 2014 [Member]

June 15, 2015 [Member]

2.75% [Member]

2.75% [Member]

2.75% Plus 1.0% [Member]

2.75% Plus 1.0% [Member]

2.75% Plus 1.0% Plus 0.25% [Member]

2.75% Plus 1.0% Plus 0.25% [Member]

First Anniversary [Member]

First Anniversary [Member]

Commonwealth of Pennsylvania Financing Authority Loan [Member]

Commonwealth of Pennsylvania Financing Authority Loan [Member]

10.25% Term Loan, Due March 2020 [Member]

10.25% Term Loan, Due March 2020 [Member]

Mortgage Loans [Member]

Mortgage Loan 1 [Member]

Mortgage Loan 2 [Member]

Mortgage Loans [Member]

Mortgage Loans [Member]

6.00% Mortgage Loan, Due December 2031 [Member]

6.00% Mortgage Loan, Due December 2031 [Member]

6.00% Mortgage Loan, Due October 2020 [Member]

6.00% Mortgage Loan, Due October 2020 [Member]

4.75% Bank Term Loans, Due January 2021 Through August 2021 [Member]

4.75% Bank Term Loans, Due January 2021 Through August 2021 [Member]

Mortgage Loan [Member]

March 12, 2014 Credit Agreement [Member]

Royalty Agreement Terms [Member]

Maximum [Member]

Royalty Agreement Terms [Member]

Maximum [Member]

Royalty Agreement Terms [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Note

Definitive Settlement Agreement [Member]

Royalty Agreement Terms [Member]

Royalty Agreement Terms [Member]

Royalty Agreement Terms [Member]

Royalty Agreement Terms [Member]

Royalty Agreement Terms [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Committed principal amount of term loan

$60,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from tranche loan

40,000,000

'

'

'

40,000,000

'

'

'

'

'

'

'

'

'

10,000,000

10,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of tranche loan

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest rate per annum

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5.00%

'

9.25%

'

'

'

'

6.00%

'

'

'

'

'

'

'

'

'

Additional interest rate on Prime Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.00%

'

'

'

'

1.50%

'

'

'

'

'

'

'

'

'

Term loan, interest rate terms

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'The Loans bear interest at 9.25% per annum plus the greater of three-month LIBOR or 1.0%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Term loan, default interest rate, fixed percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

14.25%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Term loan, default interest rate, variable percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Term loan ,default interest rate terms

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'A default interest rate of 14.25% per annum plus the greater of three-month LIBOR or 1.0%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long-term debt, due date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

31-Jan-21

12-Mar-20

'

'

'

'

'

'

31-Dec-31

'

31-Oct-20

'

'

'

'

'

Percentage of prepayment premium

'

'

'

'

6.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of repayment of debt from proceeds on sale of assets and casualty events

'

'

'

'

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net proceeds from debt

'

'

'

'

31,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt related expenses

'

'

'

'

400,000

'

'

'

'

'

'

'

40,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Royalty percentage on first $50 million of net sales

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.75%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash receipt on net sales in credit agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,000,000

'

100,000,000

'

100,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Royalty percentage on second $50 million of net sales

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Royalty percentage on net sales over $100 million

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.25%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Buy out amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

21,000,000

6,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loans determined, fair value

'

'

'

'

'

'

'

'

'

'

'

33,000,000

'

7,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of separate units reported

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loan effective rate of interest

'

'

'

'

'

'

'

'

'

'

'

17.50%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of mortgage loans

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

Mortgage loans, amount

'

'

55,756,000

'

55,756,000

'

23,871,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

33,000,000

'

'

14,250,000

3,750,000

'

'

13,347,000

13,677,000

'

3,322,000

'

1,701,000

'

'

Debt instrument floor interest rate during period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4.50%

'

'

'

'

'

'

'

'

'

Weighted average interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6.00%

6.00%

'

'

'

'

'

'

'

'

Debt Service Reserve Account

'

'

2,400,000

'

2,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Minimum balance in Debt Service Reserve Account

'

'

1,600,000

'

1,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount of loans guaranteed by U.S. Department of Agriculture

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8,000,000

'

'

'

'

'

'

'

Long-term debt, percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.25%

'

'

'

'

'

'

6.00%

'

6.00%

'

4.75%

'

'

'

Long-term debt, due date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'January 2021 through August 2021

'

'

'

Debt Instrument, Periodic Payment

'

'

'

'

'

'

'

'

'

4,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,900,000

'

Debt instrument, fee and expense paid

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Write off of unamortized deferred financing costs

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Extinguishment of debt, amount

'

'

'

'

200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Master Lease Agreement with Varilease Finance, Inc. for secured financing

'

'

'

'

'

'

'

10,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Effective interest rate

'

'

'

'

'

'

'

14.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Frequency of payment as per agreement

'

'

'

'

'

'

'

'

'27 monthly installments based upon the amount drawn

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Lease buyout rate

'

15.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Lease period

'

'2 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional lease period

'

'1 year

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Lease payment

'

'

4,800,000

'

4,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest expense

'

'

809,000

591,000

5,640,000

1,852,000

'

'

'

'

3,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from credit agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,500,000

Loan amount for financing for land and construction of current manufacturing facility

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2,250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net_Loss_Per_Share_Net_Loss_Pe

Net Loss Per Share - Net Loss Per Share (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Numerator	'	'	'	'
Net loss	($15,109)	($14,084)	($42,636)	($41,221)
Denominator	'	'	'	'
Weighted average number of shares used to compute basic net loss per share	100,007,135	81,595,444	97,135,688	78,830,613
Effect of dilutive options to purchase common stock	'	'	'	'
Weighted average number of shares used to compute diluted net loss per share	100,007,135	81,595,444	97,135,688	78,830,613
Basic and diluted net loss per share	($0.15)	($0.17)	($0.44)	($0.52)

Net_Loss_Per_Share_Additional_

Net Loss Per Share - Additional Information (Detail)	3 Months Ended		9 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Net Income Per Share [Line Items]	'	'	'	'
Incremental shares in case of profit for calculating diluted earnings per share	'	'	'	'
Restricted Stock [Member]	'	'	'	'
Net Income Per Share [Line Items]	'	'	'	'
Share excluded from calculation of basic and diluted net loss per share	2,564,631	5,666,495	2,774,977	5,200,496
Employee Stock Option [Member]	'	'	'	'
Net Income Per Share [Line Items]	'	'	'	'
Share excluded from calculation of basic and diluted net loss per share	3,429,685	7,032,057	4,985,648	8,504,634
Incremental shares in case of profit for calculating diluted earnings per share	493,490	914,744	398,727	592,309

Sanofi_Agreements_Additional_I

Sanofi Agreements - Additional Information (Detail) (Sanofi [Member])	9 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2014
	USD ($)	EUR (€)
	Product
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'
Exclusivity fees and industrialization milestone payments	$36.40	'
Up front non-refundable one-time fee	13	10
Unamortized revenue recognized	2.3	'
Ramp-up period after market entry	'4 years	'4 years
Minimum purchase per year	150,000,000	150,000,000
Milestone-based payments	15	'
Milestone-based payments, received	$5	'